Microcap Ledger Enanta Pharmaceuticals Inc $ENTA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
This page is still filling in. We publish more sections as filings are processed.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Watertown, MA
- Fiscal year end
- September 30
- Shares outstanding
- 29,125,402 [10-Q 2026-08-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jun 2026 | $50.13M | −$44.53M | −$28.83M | $33.42M | [10-Q 2026-08-12] |
| FY ended Sep 2025 | $65.32M | −$81.89M | −$19.27M | $32.30M | [10-K 2025-11-19] |
| FY ended Sep 2024 | $67.64M | −$116.05M | −$78.76M | $37.23M | [10-K 2025-11-19] |
- Quarterly cash burn
- −$9.61M
- Cash runway Estimate
- ~10.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 21,194,326 | [10-K 2024-11-27] |
| 2025-02-04 | 21,332,544 | [10-Q 2025-02-12] |
| 2025-05-01 | 21,376,581 | [10-Q 2025-05-14] |
| 2025-08-05 | 21,377,923 | [10-Q 2025-08-13] |
| 2025-11-04 | 28,862,601 | [10-K 2025-11-19] |
| 2026-02-05 | 29,019,344 | [10-Q 2026-02-11] |
| 2026-05-05 | 29,078,380 | [10-Q 2026-05-13] |
| 2026-08-07 | 29,125,402 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-02-11; declared effective 2026-02-20 [S-3 2026-02-11]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-08 | Rottinghaus Scott T. | other | 1,467 | $13.34 | [4 2026-08-10] |
| 2026-02-12 | Kowalsky Matthew Paul | grant | 1,318 | — | [4 2026-02-13] |
| 2026-02-12 | Kowalsky Matthew Paul | grant | 4,175 | — | [4 2026-02-13] |
| 2026-02-12 | Kowalsky Matthew Paul | other | 1,902 | $14.25 | [4 2026-02-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-07-02 | 8-K | Material agreement entered |
| 2026-07-02 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-23 | 8-K | Other events |
| 2026-06-18 | 8-K | Regulation FD disclosure |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Results of operations |
| 2026-03-26 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-03-26 | 8-K | Other events |
Alerts for $ENTA
Email me when Enanta Pharmaceuticals Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.